Eva L. Feldman

Eva L. Feldman is a Professor of Neurology at the University of Michigan's Michigan Medicine school and holds the James W. Albers Distinguished University Professor and Russell N. DeJong Professor titles. She directs the ALS Center of Excellence, Program for Neurology Research & Discovery, and NeuroNetwork for Emerging Therapies, focusing on translating lab findings into clinical applications for neurological diseases.

• Academic Rank: Professor of Neurology
• Leadership: Director of three major research initiatives
• Research Scope: ALS, Alzheimer's, diabetic neuropathy, and environmental neurotoxicology

Her research integrates RNA biology (mRNA stability, microRNA dysregulation, RNA exosomes) with metabolic and epigenetic mechanisms to identify early biomarkers and therapeutic targets. Current projects include exploring the cGAS/STING pathway in metabolic stress-induced cognitive decline and the impact of cyanobacterial toxins on ALS progression, reflecting her dual focus on molecular pathogenesis and public health implications.

The 2025 article trends highlight her work at the intersection of neurodegeneration, metabolic disorders, and environmental factors. Her team uses single-cell transcriptomics, multi-omics, and epidemiological modeling to unravel disease mechanisms across ALS, Alzheimer's, diabetes, and obesity-related neuropathies.

Scientific Recognition:

• Continuously NIH-funded since 1989
• Best Doctors in America listing
• Member of the National Academy of Medicine
• Fellow of the American Association for the Advancement of Science
• Award for Excellence from the American Neurological Association

Collaborative Expertise: Her lab fosters interdisciplinary partnerships with genetics, physiology, bioinformatics, and environmental science experts. She mentors students through hands-on research in high-impact projects and advocates for expanding ALS clinical research networks.

Labs & Teams: Leads the Program for Neurology Research & Discovery and NeuroNetwork for Emerging Therapies, which leverage advanced technologies for neurotherapeutic innovation. The ALS Center of Excellence under her direction drives Michigan’s mandatory ALS case reporting initiative to enhance disease surveillance.